Day 1 – Thursday, March 14, 2024
Location: Seminar Room 406/408/410
8:30 – 9:00am ET |
Registration Desk Open – Terrace Level Join WebEx |
|
|
OPENING SESSION |
||
|
9:00 – 9:05am ET |
Welcome to I-SCORE 2024 |
Leslie Ford, MD |
|
9:05 – 9:30am ET |
Developing Collaborations and Technologies to Address Challenges in Cancer Prevention and Symptom Science |
Erin Lavik, ScD |
|
9:30 – 9:50am ET |
Consortia/CP-CTNet Update |
Eva Szabo, MD |
|
9:50 – 10:00am ET |
Q&A |
All |
|
CLINICAL TRIAL REPORTS (20 min presentations, 5 min Q&A) |
Seema A. Khan, MD |
|
|
|
|
|
|
10:00 – 10:25am ET |
UAZ20-01-01 Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) |
H-H. Sherry Chow, PhD |
|
10:25 – 10:50am ET |
MDA21-06-01 A Phase 1b/II Clinical Trial of Nous-209 for Recurrent Neoantigen Immunogenicity and Cancer Immune Interception in Lynch Syndrome |
Eduardo Vilar-Sanchez, MD, PhD |
|
10:50 – 11:15am ET |
UMI21-05-01 Obeticholic Acid for Prevention in Barrett's Esophagus |
Prashanthi Thota, MD |
|
11:15 – 11:25am ET |
BREAK |
|
|
|
|
|
|
11:25 – 11:50am ET |
UWI2016-08-01 Pilot Study of Daily Exemestane in Patients with Endometrial Intraepithelial Neoplasia or Low-Grade Endometrial Cancer (EC) |
Britt Erickson, MD |
|
11:50am – 12:15pm ET |
NWU2017-09-01 Phase I Trial of Endoxifen Gel Versus Placebo Gel in Women Undergoing Breast Surgery |
Oukseub Lee, PhD |
|
12:15 – 1:00pm ET GROUP PHOTO/LUNCH BREAK |
|
|
|
ENHANCING TRIAL RECRUITMENT AND OPERATIONS |
Ellen Richmond, MS, GNP-BC |
|
|
1:00 – 1:25pm ET |
The Power and Purpose of Patient Advocates in Clinical Research |
Laurel Pracht, BS |
|
1:25 – 1:50pm ET |
Confessing Our Past, Challenging Our Present, Contemplating Our Future: Incorporating the Voice of the Community |
Quincy J. Byrdsong, EdD, CIP, CCRP |
|
1:50 – 2:15pm ET |
From FDA to CTA's: Challenges to Initiating Early Phase Clinical Trials |
|
|
2:15 – 2:35pm ET |
Communications Update |
|
|
2:35 – 3:00pm ET |
DMACC Progress and Looking Ahead |
KyungMann Kim, PhD Sue Siminski, MS, MBA |
|
3:00 – 3:30pm ET BREAK (adjourn for non-coordinators and those not on the Steering Committee) |
||
| CONCURRENT SESSIONS (Steering Committee members and Coordinators/DMACC only) | ||
|
3:30 – 6:00pm ET |
Steering Committee Meeting |
Eva Szabo, MD |
|
3:30 – 5:30pm ET |
AQuIP Coordinators’ Think Tank |
Ellen Richmond, MS, GNP-BC Division of Cancer Prevention, NCI |
|
6:00 – 9:00pm ET |
Social Hour at Botanero https://www.botanerorockville.com/ 240-474-5461 |
|
Day 2 – Friday, March 15, 2024
Location: Seminar Room 406/408/410
|
8:45 – 9:00am ET |
Registration Desk Open – Terrace Level Join WebEx
|
|
|
SCIENTIFIC SESSION: CROSS-NETWORK STUDIES |
Howard Parnes, MD |
|
|
9:00 – 9:25am ET
|
INT23-14-01 A Tamoxifen RENAISSANCE: Refining Tamoxifen dose for cancer prevention |
Seema A. Khan, MD |
|
9:25 – 9:50am ET |
INT21-05-01 A Phase IIB Clinical Trial in Lynch Syndrome test a CEA/MUC1/Brachyury Vaccine plus IL-15 Adjovant: The First Cross-Network Trial |
Ajay Bansal, MD |
|
9:50 – 10:15am ET |
INT22-09-01 Apalutamide in Non-Muscle Invasive Bladder Cancer: Emerging Knowledge of Androgen Signaling and Sex differences in Bladder Cancer |
Debasish Sundi, MD |
|
10:15 – 10:25am ET |
COFFEE BREAK |
|
|
SCIENTIFIC SESSION: HIGH-RISK COHORTS: OBESITY AND EARLY-ONSET CANCERS |
Howard Parnes, MD |
|
|
10:25 – 10:50am ET |
Weight Loss for Breast Cancer Prevention and Control |
Jennifer A. Ligibel, MD |
|
10:50 – 11:15am ET |
MDA20-02-01: Time Restricted Eating and Metformin (TEAM) in Invasive Breast (IBC) or Ductal Carcinoma in Situ Metformin (DCIS) A Randomized, Phase IIb, Window of Opportunity Presurgical Trial |
Andrea De Censi, MD |
|
11:15 – 11:40am ET |
Incretin Mimetics and Cancer |
Edward Sauter, MD, PhD |
|
11:40 – 12:05pm ET |
Obesity, Immune Surveillance and Cancer Immune Prevention/Interception |
Anda Vlad, MD, PhD |
|
12:05pm ET |
WRAP UP AND ADJOURN |
Leslie Ford, MD and Eva Szabo, MD |